Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy

Citation:
Greenhawt M, Sindher SB, Wang J, O'sullivan M, Du Toit G, Kim EH, et al. Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy. New Engl J Med. 2023;388(19):1755-66.

Keywords:
Anaphylaxis; desensitization; adverse effects; peanut allergy; allergens; randomised controlled trial

Abstract:
No approved treatment for peanut allergy exists for children younger than 4 years of age, and the efficacy and safety of epicutaneous immunotherapy with a peanut patch in toddlers with peanut allergy are unknown.